Arcus Biosciences raises ~$141.6M in public offering of 13.6M shares at $11.00/share

Arcus Biosciences, Inc.

Offered 13,636,364 shares at $11.00/share, yielding ~$141.6M net proceeds after expenses.
Proceeds to fund R&D activities, including clinical development of casdatifan, manufacturing, and general corporate purposes.
Offering closed on Feb 19, 2025; underwritten by Goldman Sachs and Leerink Partners.
Shares sold under existing shelf registration statement (Form S-3) filed with the SEC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.